Vir Biotechnology (VIR) Depreciation & Amortization (CF) (2018 - 2026)

Vir Biotechnology has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 1.95% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 9.95% YoY) and the FY2025 annual result came in at $11.7 million, down 19.77% from the prior year.
• Depreciation & Amortization (CF) slipped to $2.8 million in Q1 2026 per VIR's latest filing, from $2.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.6 million in Q1 2023 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $3.2 million and a median of $2.9 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) surged 297.32% in 2023, then sank 36.53% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $2.4 million in 2022, then surged by 87.96% to $4.5 million in 2023, then sank by 35.57% to $2.9 million in 2024, then climbed by 0.42% to $2.9 million in 2025, then slipped by 3.0% to $2.8 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.8 million, $2.9 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.